Literature DB >> 33984236

Cooperative Self-Assembled Nanoparticle Induces Sequential Immunogenic Cell Death and Toll-Like Receptor Activation for Synergistic Chemo-immunotherapy.

Yaoqi Wang1,2, Zenghui Wang1,2, Binlong Chen1,2, Qingqing Yin1,2, Meijie Pan1,2, Heming Xia1,2, Bo Zhang1,2, Yue Yan1,2, Zhujun Jiang1, Qiang Zhang1,2, Yiguang Wang1,2.   

Abstract

Anticancer immunotherapy is hampered by poor immunogenicity and a profoundly immunosuppressive microenvironment in solid tumors and lymph nodes. Herein, sequential pH/redox-responsive nanoparticles (SRNs) are engineered to activate the immune microenvironment of tumor sites and lymph nodes. The two-modular SRNs could sequentially respond to the acidic tumor microenvironment and endosome compartments of dendritic cells (DCs) to precisely deliver doxorubicin (DOX) and imidazoquinolines (IMDQs). In the tumor microenvironment, released DOX triggers immunogenic cell death. In sentinel lymph nodes, the IMDQ nanoparticle module is dissociated in the acidic endosome compartment to specifically stimulate toll-like receptor 7/8 for DC maturation. Thus, the orchestrated nanoparticle system could enhance the infiltration of CD8α+ T cells in tumors and provoke a strong antitumor immune response toward primary and abscopal tumors in B16-OVA and CT26 tumor-bearing mice models. The cooperative self-assembled nanoparticle strategy provides a potential candidate of nanomedicine to advance the synergistic cancer chemo-immunotherapy.

Entities:  

Keywords:  chemo-immunotherapy; immunogenic cell death; pH/redox sequential responsiveness; polymer−drug conjugate; toll-like receptor agonist

Year:  2021        PMID: 33984236     DOI: 10.1021/acs.nanolett.1c00977

Source DB:  PubMed          Journal:  Nano Lett        ISSN: 1530-6984            Impact factor:   11.189


  5 in total

Review 1.  Nanomedicine-enabled chemotherapy-based synergetic cancer treatments.

Authors:  Wencheng Wu; Yinying Pu; Jianlin Shi
Journal:  J Nanobiotechnology       Date:  2022-01-04       Impact factor: 10.435

2.  Non-cytotoxic nanoparticles re-educating macrophages achieving both innate and adaptive immune responses for tumor therapy.

Authors:  Shengmei Wang; Xuanjun Liu; Minghua Yang; Linqi Ouyang; Jinsong Ding; Shengfeng Wang; Wenhu Zhou
Journal:  Asian J Pharm Sci       Date:  2022-06-10       Impact factor: 9.273

Review 3.  When Natural Compounds Meet Nanotechnology: Nature-Inspired Nanomedicines for Cancer Immunotherapy.

Authors:  Linna Yu; Yi Jin; Mingjie Song; Yu Zhao; Huaqing Zhang
Journal:  Pharmaceutics       Date:  2022-07-30       Impact factor: 6.525

4.  Combining immune checkpoint blockade with ATP-based immunogenic cell death amplifier for cancer chemo-immunotherapy.

Authors:  Jiulong Zhang; Xiaoyan Sun; Xiufeng Zhao; Chunrong Yang; Menghao Shi; Benzhuo Zhang; Haiyang Hu; Mingxi Qiao; Dawei Chen; Xiuli Zhao
Journal:  Acta Pharm Sin B       Date:  2022-05-16       Impact factor: 14.903

5.  Inhibition of post-surgery tumour recurrence via a sprayable chemo-immunotherapy gel releasing PD-L1 antibody and platelet-derived small EVs.

Authors:  Jian Zhao; Hao Ye; Qi Lu; Kaiyuan Wang; Xiaofeng Chen; Jiaxuan Song; Helin Wang; Yutong Lu; Maosheng Cheng; Zhonggui He; Yinglei Zhai; Haotian Zhang; Jin Sun
Journal:  J Nanobiotechnology       Date:  2022-02-02       Impact factor: 10.435

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.